M Rinzivillo1, D Prosperi2, F Mazzuca3,4, L Magi1, E Iannicelli5,6, E Pilozzi4,7, G Franchi2, A Laghi5,6, B Annibale1,6, A Signore2,6, F Panzuto8. 1. Digestive Disease Unit, ENETS Center of Excellence, Sant'Andrea University Hospital, Via di Grottarossa 1035, 00189, Rome, Italy. 2. Nuclear Medicine Unit, ENETS Center of Excellence, Sant'Andrea University Hospital, Rome, Italy. 3. Medical Oncology Unit, ENETS Center of Excellence, Sant'Andrea University Hospital, Rome, Italy. 4. Department of Clinical and Molecular Medicine, "Sapienza" University of Rome, Rome, Italy. 5. Radiology Unit, ENETS Center of Excellence, Sant'Andrea University Hospital, Rome, Italy. 6. Department of Medical-Surgical Sciences and of Translational Medicine, "Sapienza" University of Rome, Rome, Italy. 7. Pathology Unit, ENETS Center of Excellence, Sant'Andrea University Hospital, Rome, Italy. 8. Digestive Disease Unit, ENETS Center of Excellence, Sant'Andrea University Hospital, Via di Grottarossa 1035, 00189, Rome, Italy. fpanzuto@ospedalesantandrea.it.
Abstract
PURPOSE: This study aims to identify in patients with neuroendocrine neoplasia (NEN) the potential correlation between FDG-PET findings and responses to everolimus therapy to identify predictors of long-term efficacy. METHODS: Retrospective analysis of patients with sporadic, advanced, progressive NEN treated with everolimus was performed based on the available data on FDG-PET patients obtained before commencing therapy. Data are expressed as the median (25-75th IQR). Risk factor analysis and survival analysis were performed by logistic regression and Cox proportional hazard regression and the determination of Kaplan-Meier curves, as appropriate. RESULTS: Sixty-six patients were evaluated (NET G1 19.7%, NET G2 75.7%, and NET G3 4.6%), including 45.4% with positive FDG-PET findings. Overall, disease stabilization and a partial response were achieved for 71.2% and 6% of patients, respectively. A long-term response (> 24 months) was observed in 33% of patients. Ki67 was the only predictor of tumor progression (p = 0.03). No significant difference in clinical outcomes was observed between patients with positive or negative FDG-PET findings (median PFS was 24 months and 18 months, respectively, p = 0.337; the disease control rate was 83.3% and 70%, respectively, p = 0.245). CONCLUSIONS: Everolimus is a valid therapeutic option for advanced, progressive, well-differentiated NEN, even in patients with positive FDG-PET findings.
PURPOSE: This study aims to identify in patients with neuroendocrine neoplasia (NEN) the potential correlation between FDG-PET findings and responses to everolimus therapy to identify predictors of long-term efficacy. METHODS: Retrospective analysis of patients with sporadic, advanced, progressive NEN treated with everolimus was performed based on the available data on FDG-PET patients obtained before commencing therapy. Data are expressed as the median (25-75th IQR). Risk factor analysis and survival analysis were performed by logistic regression and Cox proportional hazard regression and the determination of Kaplan-Meier curves, as appropriate. RESULTS: Sixty-six patients were evaluated (NET G1 19.7%, NET G2 75.7%, and NET G3 4.6%), including 45.4% with positive FDG-PET findings. Overall, disease stabilization and a partial response were achieved for 71.2% and 6% of patients, respectively. A long-term response (> 24 months) was observed in 33% of patients. Ki67 was the only predictor of tumor progression (p = 0.03). No significant difference in clinical outcomes was observed between patients with positive or negative FDG-PET findings (median PFS was 24 months and 18 months, respectively, p = 0.337; the disease control rate was 83.3% and 70%, respectively, p = 0.245). CONCLUSIONS:Everolimus is a valid therapeutic option for advanced, progressive, well-differentiated NEN, even in patients with positive FDG-PET findings.
Authors: Mei Sim Lung; Rodney J Hicks; Nick Pavlakis; Emma Link; Michael Jefford; Benjamin Thomson; David K Wyld; Winston Liauw; Timothy Akhurst; Narmatha Kuru; Michael Michael Journal: Asia Pac J Clin Oncol Date: 2020-02-07 Impact factor: 2.601
Authors: A Faggiano; P Ferolla; F Grimaldi; D Campana; M Manzoni; M V Davì; A Bianchi; R Valcavi; E Papini; D Giuffrida; D Ferone; G Fanciulli; G Arnaldi; G M Franchi; G Francia; G Fasola; L Crinò; A Pontecorvi; P Tomassetti; A Colao Journal: J Endocrinol Invest Date: 2011-11-09 Impact factor: 4.256
Authors: Jaume Capdevila; Enrique Grande; Rocío García-Carbonero; Marc Simó; Mª Isabel Del Olmo-García; Paula Jiménez-Fonseca; Alberto Carmona-Bayonas; Virginia Pubul Journal: Oncologist Date: 2022-04-05